Abstract Number: 971 • 2016 ACR/ARHP Annual Meeting
Reliability and Minimal Clinically Important Differences (MCID) of Forced Vital Capacity: Post-Hoc Analyses from the Scleroderma Lung Studies (SLS-I and II)
Background/Purpose: Forced vital capacity (FVC) is used as a primary outcome measure in clinical trials of systemic sclerosis-related interstitial lung disease (SSc-ILD). Minimally Clinically Important…Abstract Number: 973 • 2016 ACR/ARHP Annual Meeting
Clinical Characterization of Patients with World Health Organization Group 2 Pulmonary Hypertension in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Cohort
Background/Purpose: Pulmonary hypertension (PH) is a leading cause of death in patients (pts) with Systemic Sclerosis (SSc). The World Health Organization (WHO) classifies PH into…Abstract Number: 974 • 2016 ACR/ARHP Annual Meeting
Diffuse Scleroderma, Male Sex, and Myopathy Are Associated with Severe Gastrointestinal Dysmotility in Scleroderma
Background/Purpose: Despite the fact that up to 90% of scleroderma (SSc) patients are affected by gastrointestinal (GI) dysmotility, features associated with severe GI disease are…Abstract Number: 1189 • 2016 ACR/ARHP Annual Meeting
Inpatient Trends for Adults with Scleroderma in the United States: A 20 Year Analysis
Abstract Number: 1432 • 2016 ACR/ARHP Annual Meeting
The EULAR Systemic Sclerosis Impact of Disease Score – a New Patient-Reported Outcome Measure for Patients with Systemic Sclerosis Under Development
Background/Purpose: Patient reported outcome measures (PROM) are required as key outcomes in disease modifying therapeutic trials in systemic sclerosis (SSc). A PROM tool in SSc,…Abstract Number: 1865 • 2016 ACR/ARHP Annual Meeting
Urinary Cell Adhesion Molecules As Markers of Renal Involvement in Systemic Sclerosis
Background/Purpose: Renal involvement in systemic sclerosis (SSc) includes scleroderma renal crisis as well as progressive organ fibrosis. Detection and management of these disease complications is…Abstract Number: 1877 • 2016 ACR/ARHP Annual Meeting
Confirmatory Factor Analysis and Assessment of Differential Item Functioning of the Satisfaction with Appearance Scale in Systemic Sclerosis: A Comparison Across Sex, Race/Ethnicity and Disease Subtype
Background/Purpose: The Satisfaction with Appearance Scale (SWAP) has been used to assess dissatisfaction with appearance and social discomfort relative to disfigurement in systemic sclerosis (scleroderma,…Abstract Number: 1880 • 2016 ACR/ARHP Annual Meeting
A Large Proportion of Patients in an Early Systemic Sclerosis-Associated Interstitial Lung Disease Cohort Have Coexisting Pulmonary Hypertension
Background/Purpose: Systemic Sclerosis (SSc) is a multi-organ system disease manifested by fibrosis, vascular damage and dysregulation of the immune system. The leading causes of death…Abstract Number: 2019 • 2016 ACR/ARHP Annual Meeting
Faces in Motion: Clinical Subtyping in Scleroderma Using Changes in Forced Vital Capacity
Background/Purpose: Prognostication in scleroderma has historically depended on using static measures such as antibody status and extent of skin involvement to stratify risk of mortality…Abstract Number: 2895 • 2016 ACR/ARHP Annual Meeting
Adaptation of UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract 2.0 Questionnaire into Turkish
Background/Purpose: Nearly 90% of patients with scleroderma (SSc) have gastrointestinal tract(GIT) involvement in variable severities and is a challenging process for clinicians.The University of California…Abstract Number: 2902 • 2016 ACR/ARHP Annual Meeting
Preliminary Evaluation of Gastroesophageal Reflex Disease Outcome Measures in Scleroderma– Scleroderma Clinical Trials Consortium Gastrointestinal Working Group
Background/Purpose: Gastrointestinal tract (GIT) involvement occurs in approximately 95% of patients with systemic sclerosis (SSc). There is consensus in the Scleroderma Clinical Trials Consortium (SCTC)…Abstract Number: 825 • 2016 ACR/ARHP Annual Meeting
KL-6 and Not CCL-18 Is a Predictor of Early Progression in Systemic Sclerosis Related Interstitial Lung Disease
Background/Purpose: Pneumoproteins are attractive biomarker candidates in systemic sclerosis (SSc) related interstitial lung disease (ILD) because they are easily obtainable and lung-specific. KL-6 and CCL-18…Abstract Number: 2910 • 2016 ACR/ARHP Annual Meeting
Work Productivity in Systemic Sclerosis and Association with Health Related Quality of Life
Background/Purpose: We sought to assess work productivity, factors associated with reduced productivity, and the relationship between work productivity and health-related quality of life (HRQoL) in…Abstract Number: 826 • 2016 ACR/ARHP Annual Meeting
Exercise Echocardiography Predicts Future Development of Pulmonary Hypertension in a High-Risk Cohort of Scleroderma Patients
Background/Purpose: Pulmonary hypertension (PH) is the leading cause of scleroderma related deaths and is often detected late in the disease course. Early identification of patients…Abstract Number: 828 • 2016 ACR/ARHP Annual Meeting
Survival and Health-Related Quality of Life in Incident Systemic Sclerosis Related Pulmonary Arterial Hypertension: A Multicentre Australian Cohort Study
Background/Purpose: Pulmonary arterial hypertension (PAH) is the leading cause of systemic sclerosis (SSc) related mortality. We sought to determine survival, predictors of mortality, and health…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 8
- Next Page »